Agilent Technologies reports a major sale to Metabolomics Australia (MA), which will provide metabolomics services to Australian researchers
Valued at approximately $2.5 million, the order includes multiple HPLC, LC/MS, GC, GC/MS and CE instruments, plus specific software to facilitate analysis of metabolomic data.
"Metabolomics Australia performed a very thorough evaluation of all competitive technology to arrive at their decision - we are clearly delighted that they have chosen Agilent," said Rod Minnett, Agilent Australia operations manager.
"Much of this success comes from ongoing efforts to satisfy the needs of the MA consortium...
listening to them, understanding their needs and building a high level of trust".
MA is a national collaborative research infrastructure strategy centre that is managed through a new coordinating body, Bioplatforms Australia .
It is structured as a network of geographic nodes in Victoria (University of Melbourne), Western Australia (University of Western Australia and Murdoch University), South Australia (Australian Wine Research Institute) and Queensland (University of Queensland).
MA focuses on providing services to researchers in medical, agricultural and environmental applications of metabolomics.
"We are excited at the prospect of working closely with Agilent to provide a holistic solution that embraces high-throughput data generation analysis and interpretation," said professor Tony Bacic, MA platform convenor.
"Agilent provides a tremendous breadth of critical technologies to support metabolomics analyses," said Ken Miller, Agilent senior global marketing manager for LC/MS products.
"The products chosen by MA will provide comprehensive analysis capabilities, enormous capacity, and an efficient workflow for metabolome elucidation and targeted metabolite quantitation."
